TNGX compared with RVMD: revenue, margins and what each company keeps, and the suppliers and customers both name

TNGXTango Therapeutics, Inc.

Mkt capRevenueRevenue

RVMDRevolution Medicines, Inc.

Mkt capRevenueRevenue

Compare

TNGXTango Therapeutics, Inc.

RVMDRevolution Medicines, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

TNGX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±11.4%▼−4.81%×0.42

May 14 '26±14.3%▼−2.51%×0.17

Q1 FY26±42.5%▲+36.28%×0.85

Jan 8 '26±30.3%▼−6.23%×0.20

RVMD2 of 4 reports

1 of 2at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±9.7%▼−11.04%×1.13

Q2 FY26±7.9%▲+0.26%×0.04

= impliedTNGX realized, solidRVMD realized, hatchedOne scale, both sides: full bar = 43%× = |realized| ÷ impliedspan: TNGX 215d · RVMD 91dSource: market data

TNGXTango Therapeutics, Inc.

21.49▲+2.96%· post 21.49· delayed

Mkt cap$3.6BRevenue$54MQ3 FY25Revenue$42MFY24

RVMDRevolution Medicines, Inc.

192.54▲+8.38%· post 192.56· delayed

After hoursNov 6 '26delayed

Mkt cap$38.4BRevenue$198MQ3 FY26Revenue—

Compare

After hoursNov 6 '26delayed

TNGXTango Therapeutics, Inc.

RVMDRevolution Medicines, Inc.

21.49▲+2.96%post 21.49delayed

Price

192.54▲+8.38%post 192.56delayed

$3.6B

Mkt cap

$38.4B

Q3 FY25$54M

Revenue

$198MQ3 FY26

FY24$42M

Revenue

—

TNGX21.49▲+2.96%vsRVMD192.54▲+8.38%After hoursNov 6 '26delayed